Top 3 ASX Penny Stocks Under $1: Updated List
Last Updated on 21st September 2026
These are the top three Austrailian Shares which are trading below $1, led by high growth potential, a solid balance sheet and strong business fundamentals.
1. Amaero Inc. (ASX: 3DA)
Amaero Inc. (ASX: 3DA) is one of the top industrial ASX stocks with a huge upside potential, currently trading at $0.26 with a market capitalisation of $257.9M.
Amerco had announced on 19 August 2026 its audited financial report for the period ended at June 2026.
The revenue from ordinary activities has shown a massive growth of 375.9% to $18.1M, meeting the earlier stated management guidance. This includes:
-
$15.6M from the powder segment
-
$2.69M from PM-HIP
3DA has reported a net tangible asset per CDI of $0.07.
Backlog and Contracts
It has a backlog of $23.1M, including $8.5M of additional contracts since 30 June. Out of the total, $12.9M relates to work currently scheduled to be completed by 31 December 2026.
They have also received a $6.5M contract from the US Department of War for the development of alternative refractory alloy powders and a 13-month development program expected to be completed in August 2027.
2. Austco Healthcare Limited (ASX: AHC)
Austco Healthcare Limited (ASX: AHC) is one of the top healthcare ASX stocks with huge upside potential, currently trading below A$1. It has a current market capitalisation of $93.68M.
AHC had received on 17 September 2026 its annual report to shareholders for the period ended at June 2026.
Austco has reported a revenue of $94.6M, a 16% increase compared to last year. Gross margin improved to 53.4% from 52% in FY25.
EBITDA grew 14% to $14.9M, with an EBITDA margin of 15.8%. Statutory net profit after tax grew by 52% to $9M.
Financial Position
Cash generated from operating activities increased to $12.5M, and there was a capex & development expense of ~$2.8B.
The closing cash balance jumped to ~$16.3M with no material borrowings and a net asset balance of $62.1M.
Contract Wins and Acquisition
Austco has delivered strong operational performance with multiple contract wins, as they have converted their existing Jurong relationship into a $4.2M ten year recurring revenue with approximately $420k annually till 2036.
They also received a $1.85M phase one purchase orders received and $1.1M nurse call contract from the Warrnambool base hospital.
The recent acquisition of Medical Communications Systems Pty Ltd has added a net incremental revenue of $1.88M and $0.82M as incremental EBITDA on a full year basis.
3. BrainChip Holdings Limited (ASX: BRN)
BrainChip Holdings Limited (ASX: BRN) is one of the top technology based ASX stocks which is currently trading below $1 with a current market capitalisation of $307.3M.
BrainChip had announced on 26 September 2026 its Q2 2026 investor presentation for the period ended at June 2026.
It highlights the commercialisation of its Akida Edge AI technology, with AKD 1500 chips creating a new revenue stream.
BRN had also announced on 26 August 2026 its half yearly financial report for the period ended at June 2026.
Revenue from continuing operations increased by 19% YoY to US$1.2M and reported a loss for the period attributable to members of US$12M.
The net tangible assets per share increased to 0.85 US cents per share.
BRN has reported the cash and cash equivalents of US$20.3M compared to US$13.5M in FY25.
Source: Company Announcements
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
TOP ASX STOCKS WORTH WATCHTING
- ✓ Instant Access
- ✓ No Credit Card Required
- ✓ Free to join · No spam
Free to join · No spam · Unsubscribe anytime
By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.
ASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
